LA JOLLA, Calif.--(BUSINESS WIRE)--Sevion Therapeutics (OTCQB:SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that it has entered into a research agreement with Avidity NanoMedicines LLC related to the use of Sevion’s chimerasome technology for delivery of nucleic acids. Terms of the agreement were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
